Recognition of these patterns by TLRs triggers downstream pathways, ultimately leading to the production of pro‐inflammatory cytokines, the maturation, and the activation of APCs.[11b] Preclinical data demonstrated the anti‐tumor activity of TLR agonists in multiple cancer types[11b] while two TLR agonists, Imiquimod (TLR7 agonist) and Bacillus Calmette‐Guérin (BCG) (TLR2/4 agonist) have been approved by the Food and Drug Administration (FDA). The gene discussed is TLR7; the disease is neoplasm.